Navigation Links
Genaera Corporation Presents Phase 1 Data for Trodusquemine (MSI-1436) at the North American Association for the Study of Obesity Annual Meeting
Date:10/23/2007

th a four day, in-house study period. Post dosing evaluations were conducted for 72 hours in-house, and follow-up visits were scheduled on days seven, 14 and 21.

In this trial, trodusquemine was well tolerated, and there were no serious adverse events reported. In addition to the favorable safety profile of this study, the pharmacokinetic profile of trodusquemine showed a consistent pattern with minimal subject-to-subject variability and linearity across the range of doses studied.

"The safety, tolerability and pharmacokinetics of trodusquemine observed in this study are consistent with the results achieved in preclinical studies," stated Michael Gast, M.D., Ph.D., Executive Vice President and Chief Medical Officer of Genaera. "We look forward to advancing trodusquemine through the clinic in our next set of clinical trials as we study patients with both obesity and type 2 diabetes so that we may potentially provide a monotherapy option for patients afflicted by these disorders."

The Company expects to conduct its second ascending single dose Phase 1 clinical trial (Study MSI-1436C-103) of trodusquemine in obese type 2 diabetics. The trial will evaluate the PK and safety of trodusquemine in this population as well as provide the first opportunity to study short-term glucose control indices, glucose tolerance and insulin sensitivity.

The poster presented at NAASO, "First in Human Use of MSI-1436 (Trodusquemine) a Centrally and Peripherally Acting Selective PTP1B Inhibitor" will be presented today from 9:00 a.m. to 2:30 p.m., Central Time. Clinical researchers from Genaera will be available at the poster from 1:00 p.m. to 2:30 p.m., Central Time to discuss the poster presentation.

About Trodusquemine

Trodusquemine (MSI-1436) is the first drug candidate that acts both centrally and peripherally to selectively inhibit the established and validated enzyme target, protein tyrosine phosphatase 1B (PTP-1B). The dual locations of MSI-1436 a
'/>"/>

SOURCE Genaera Corporation
Copyright©2007 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related medicine technology :

1. Genaera Presents Preclinical Data on Trodusquemine (MSI-1436) for the Treatment of Obesity at the American Diabetes Association 67th Scientific Session
2. Genaera to Present Preclinical Data on Trodusquemine for the Treatment of Obesity at the American Diabetes Association 67th Scientific Sessions
3. Alfacell Corporation to Present at C.E. Unterberg, Towbin Emerging Growth Opportunities Conference
4. Millipore Corporation Announces New ReNcell Data from Collaboration with ReNeuron
5. NanoBio Corporation Announces Positive Phase 1 Clinical Results for Topical Treatment for Onychomycosis
6. Alba Therapeutics Corporation Reports Preliminary Phase IIa Clinical Trial Results for AT-1001 for the Treatment of Celiac Disease
7. EpiCept Corporation to Present New NP-1 Data at American Pain Society Meeting
8. Inspiration Biopharmaceuticals Presents Data From Hemophilia Program at International Society On Thrombosis and Haemostasis (ISTH) Annual Meeting
9. European Society for Medical Oncology (ESMO) Presents Data from the Clinical Trial of MediGenes Cancer-Killing Virus in Press Conference
10. Cytogen Presents Phase 1 Data Showing Promising Antitumor Activity and Safety Profile of Quadramet at International Myeloma Workshop
11. SemBioSys Presents Positive Insulin Data at the American Diabetes Association Conference
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/24/2014)... , Dec. 23, 2014  The American ... blood pressure target for people with diabetes and ... or high doses of statins, in keeping with ... enacted by the American College of Cardiology (ACC) ... reflected in the most recent changes to the ...
(Date:12/24/2014)... N.C. , Dec. 23, 2014  Medical Science ... As the key link between the medical device industry ... even more in the coming years as the device ... According to research by benchmarking firm, Best ... can gain an important edge is by harnessing new ...
(Date:12/22/2014)... Research and Markets ( http://www.researchandmarkets.com/research/h3xm6q/us ) ... Blood Glucose Market" report to their offering. ... market insight focuses on the developments in the self-monitoring ... . Reimbursement analysis and the effects of competitive ... than 73 SMBG meters have been performed, based on ...
Breaking Medicine Technology:New Standards of Care Provide Guidelines for Statin Use for People with Diabetes to Prevent Heart Disease 2New Standards of Care Provide Guidelines for Statin Use for People with Diabetes to Prevent Heart Disease 3New Standards of Care Provide Guidelines for Statin Use for People with Diabetes to Prevent Heart Disease 4Role of Medical Science Liaisons Evolving in Medical Device Sector 2US Self-monitoring Blood Glucose Market 2
...   Syndax Pharmaceuticals, Inc ., a clinical-stage epigenetics oncology ... 2 clinical trials with entinostat in combination and as ... conferences.  San Antonio Breast Cancer ... randomized, double-blind, placebo-controlled, phase 2 study of exemestane with ...
...  Henry Schein, Inc., (NASDAQ: HSIC ), the ... office-based practitioners, announced today that Stanley Bergman, Chairman and ... the Company,s Executive Vice President and Chief Financial Officer, ... on December 6.  The conference is being held at ...
Cached Medicine Technology:Multiple Data Presentations on Syndax Pharmaceutical's Entinostat at Upcoming Scientific Conferences 2Multiple Data Presentations on Syndax Pharmaceutical's Entinostat at Upcoming Scientific Conferences 3Multiple Data Presentations on Syndax Pharmaceutical's Entinostat at Upcoming Scientific Conferences 4Multiple Data Presentations on Syndax Pharmaceutical's Entinostat at Upcoming Scientific Conferences 5Henry Schein to Present at the NASDAQ OMX 27th Investor Program 2
(Date:12/25/2014)... December 26, 2014 Recently, iFitDress.com, the popular ... women, has announced its new selection of black one-shoulder ... on sale now; they are available at discounted prices, up ... “The promotion will last for three weeks only. You know, ... Those who are interested in our new items can visit ...
(Date:12/25/2014)... 2014 Helen Harris’ RP (Retinitis Pigmentosa) ... California after an 8 year battle with breast cancer. ... evening in her home in Woodland Hills California after ... , As the founder and volunteer ... pioneered and championed many of today's greatest breakthroughs in ...
(Date:12/25/2014)... common during the holidays, but there are strategies that can ... arrive at a party hungry. It may seem logical to ... party, but deprivation leads to hunger, and hunger leads to ... Mount Kisco, N.Y., said in a hospital news release. ... to have a snack before attending a party when you ...
(Date:12/25/2014)... 25, 2014 “ SmileStix ” was featured ... the latest and coolest mobile applications on the iOS, Android, ... host of NewsWatch, conducted the app review and shared with ... personal stickers. , The old saying goes, “A picture says ... words that can describe a single image, because each picture ...
(Date:12/24/2014)... Wauwatosa, Wi (PRWEB) December 25, 2014 ... who are unable to afford certain items. During the holiday ... , "We collected over 70 toys," says Dr. Sara Mahalko-Leonhardt, ... myself and staff such joy, knowing that we are able ... any present had it not been for the generosity of ...
Breaking Medicine News(10 mins):Health News:iFitDress.com: Black One-Shoulder Cocktail Dresses for 2015 2Health News:RP International founder, Helen Harris Dies on Christmas Eve Just Hours Before Her Holiday Television Broadcast to Raise Funds to Cure Blindness was Broadcasted Nationally 2Health News:RP International founder, Helen Harris Dies on Christmas Eve Just Hours Before Her Holiday Television Broadcast to Raise Funds to Cure Blindness was Broadcasted Nationally 3Health News:RP International founder, Helen Harris Dies on Christmas Eve Just Hours Before Her Holiday Television Broadcast to Raise Funds to Cure Blindness was Broadcasted Nationally 4Health News:An Application to Create Custom Stickers was Featured on NewsWatch Television on December 19, 2014 2Health News:AlignLife of Wauwatosa Brings Joy to Less Fortunate Families 2
... ... season, FORT WORTH, Texas, Nov. 13 ... Jude,during the 2008 holiday shopping season for the 5th anniversary of the,Thanks and ... RadioShack is asking customers to "Give thanks,for the healthy kids in your life, ...
... to emphasize smoking prevention for young girls has been ... Medical School (DMS). The safe, online patient education site ... prevent smoking in young girls 8-11 years old). , ... the siteNo Smoking Room.Org ( www.nosmokingroom.org ) is designed ...
... Nov. 13 NBTY, Inc. (NYSE:,NTY) (http://www.NBTY.com ), ... announced that Arthur Rudolph, its Founder,and a member of ... plan to sell a portion of his NBTY stock ... asset diversification and liquidity. The stock,trading plan was adopted ...
... (Nasdaq: AMLN ) will be presenting at the ... November,19, 2008 at 8:30 a.m. ET. Daniel M. Bradbury, ... providing a corporate overview., The live presentation will ... following the event. The Web cast and recording will ...
... $3.8 million Innovator Award, from the Department of Defense, ... renowned cancer researcher at the University of California, Santa ... is known for his innovative, interdisciplinary research. "This is ... them," said Ruoslahti. "I am very happy at being ...
... Nov. 13 Debiopharm Group,(Debiopharm), a global ... conditions and particularly oncology, today,announced that the ... month formulation,of Trelstar(R) (triptorelin pamoate) has been ... Food and Drug Administration (FDA). Trelstar(R) is ...
Cached Medicine News:Health News:RadioShack Partners With St. Jude Children's Research Hospital(R) on the 5th Anniversary of the Thanks and Giving(R) Campaign 2Health News:RadioShack Partners With St. Jude Children's Research Hospital(R) on the 5th Anniversary of the Thanks and Giving(R) Campaign 3Health News:Innovative new Web site empowers young girls to live smoke-free 2Health News:NBTY Founder Adopts Rule 10b5-1 Trading Plan 2Health News:Cancer researcher receives $3.8 million award from US Department of Defense 2Health News:Debiopharm Announces U.S. NDA Filing of Trelstar(R) 6-Month Formulation for Locally Advanced or Metastatic Prostate Cancer 2
DCR Set, Angled....
... The Leica CM3050 S Cryostat ... with excellent safety standards for ... applications. The Leica CM3050 S ... for all cryosectioning research applications ...
... The Bright 7500 is a freestanding ... liquid decontamination system and a radial ... to cut a wide range of ... effective for use in high biohazard ...
... - a vision becomes reality. Numerous ... the users many benefits.,The Cryo-Star is ... retraction that incorporates a unique refrigeration ... cooling. This facilitates applications in both ...
Medicine Products: